Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2016-02-03 Major Shareholding Noti…
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
SC 13G LGNDZ
Major Shareholding Notification
2016-02-03 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-01-26 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 22, 2016, reporting the entry into a material definitive agreement, specifically a Second Amendment to a Loan and Security Agreement. The content focuses on amendments to loan terms, interest rates, maturity dates, and repayment conditions. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The document is a current report disclosing a financing agreement amendment, which fits the category of Capital/Financing Update (CAP). The document length is about 5,013 characters, which is sufficient to contain substantive information about the financing update rather than just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2016-01-26 English
Regulatory Filings 2016
Regulatory Filings
2016-01-25 English
PRIMARY DOCUMENT
Director's Dealing
2016-01-23 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content specifically details the approval of base salary increases and payment of bonuses to named executive officers, which relates to changes in executive compensation. This fits the category of Board/Management Information (MANG), as it announces changes related to senior management compensation. The document is not an annual or quarterly report, audit report, or earnings release, nor is it a proxy statement or remuneration report. It is a standalone current report focusing on management compensation changes.
2016-01-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.